• Holiday E-Commerce Hits Record High, Despite 6 Billion Out-Of Stock Messages, Adobe Reports

    10 days ago - By Forbes

    The latest online sales figures from Adobe Analytics demonstrate that the pandemic created a net new consumer base of online shoppers.
    Read more ...

     

  • Dyne Therapeutics Reaches New 52-Week Low at $10.40

    Dyne Therapeutics Reaches New 52-Week Low at $10.40

    10 days ago - By ETF Daily News

    Dyne Therapeutics, Inc. 's share price reached a new 52-week low during mid-day trading on Monday. The company traded as low as $10.40 and last traded at $10.52, with a volume of 245 shares trading hands. The stock had previously closed at $10.88.
    Separately, Zacks Investment Research cut shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, November 9th.
    The business has a fifty day simple moving average of $13.40 and a two-hundred day simple moving average of $15.81. The company has a market cap of $559.08 million, a PE ratio of -4.25 and a...
    Read more ...

     

  • DoubleVerify Reaches New 12-Month Low at $26.44

    DoubleVerify Reaches New 12-Month Low at $26.44

    10 days ago - By ETF Daily News

    DoubleVerify Holdings, Inc. 's stock price hit a new 52-week low on Monday. The company traded as low as $26.44 and last traded at $26.48, with a volume of 2565 shares. The stock had previously closed at $27.42.
    A number of brokerages have weighed in on DV. Barclays reduced their price target on DoubleVerify from $42.00 to $37.00 and set an “equal weight” rating for the company in a research report on Monday, October 18th. Cannonball Research began coverage on DoubleVerify in a research report on Monday, November 22nd. They issued a “buy” rating and a $42.00 price target for the company...
    Read more ...

     

  • Allogene Therapeutics Reaches New 52-Week Low at $11.80

    Allogene Therapeutics Reaches New 52-Week Low at $11.80

    10 days ago - By ETF Daily News

    Allogene Therapeutics, Inc. 's share price hit a new 52-week low during trading on Monday. The stock traded as low as $11.80 and last traded at $11.97, with a volume of 88670 shares changing hands. The stock had previously closed at $13.46.
    A number of equities analysts have recently weighed in on ALLO shares. Jefferies Financial Group reaffirmed a “buy” rating on shares of Allogene Therapeutics in a research note on Friday, October 8th. HC Wainwright restated a “buy” rating and issued a $43.00 price target on shares of Allogene Therapeutics in a research note on Tuesday. William Blair...
    Read more ...

     

  • Clairvest Group Reaches New 52-Week High at $69.57

    Clairvest Group Reaches New 52-Week High at $69.57

    10 days ago - By ETF Daily News

    Clairvest Group Inc. 's share price reached a new 52-week high on Monday. The stock traded as high as C$69.57 and last traded at C$69.57, with a volume of 1147 shares. The stock had previously closed at C$63.18.
    The company has a current ratio of 5.26, a quick ratio of 4.94 and a debt-to-equity ratio of 0.35. The firm's 50 day moving average price is C$61.04 and its two-hundred day moving average price is C$60.64. The company has a market capitalization of C$1.02 billion and a price-to-earnings ratio of 9.13.
    Clairvest Group last posted its quarterly earnings results on Thursday, November...
    Read more ...

     

  • Molecular Partners Sets New 1-Year High at $21.46

    Molecular Partners Sets New 1-Year High at $21.46

    10 days ago - By ETF Daily News

    Molecular Partners AG 's share price hit a new 52-week high during mid-day trading on Monday. The stock traded as high as $21.46 and last traded at $19.82, with a volume of 10101 shares. The stock had previously closed at $16.51.
    Several research firms have commented on MOLN. Zacks Investment Research raised shares of Molecular Partners from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a report on Thursday, January 6th. SVB Leerink restated a “buy” rating on shares of Molecular Partners in a research note on Thursday, December 16th. One research analyst...
    Read more ...

     

  • VBI Vaccines Reaches New 12-Month Low at $2.01

    VBI Vaccines Reaches New 12-Month Low at $2.01

    10 days ago - By ETF Daily News

    VBI Vaccines Inc. shares reached a new 52-week low on Monday. The company traded as low as $2.01 and last traded at $2.01, with a volume of 21681 shares. The stock had previously closed at $2.12.
    A number of brokerages have issued reports on VBIV. Jefferies Financial Group assumed coverage on shares of VBI Vaccines in a research note on Thursday, December 30th. They issued a “buy” rating and a $6.00 price objective on the stock. Zacks Investment Research downgraded VBI Vaccines from a “hold” rating to a “sell” rating in a research note on Friday, December 31st.
    The company has a...
    Read more ...

     

  • Beazley Reaches New 52-Week High at $491.10

    Beazley Reaches New 52-Week High at $491.10

    10 days ago - By ETF Daily News

    Beazley plc shares reached a new 52-week high during mid-day trading on Monday. The stock traded as high as GBX 491.10 and last traded at GBX 487.50 , with a volume of 58669 shares changing hands. The stock had previously closed at GBX 485.30 .
    Several research firms recently issued reports on BEZ. Barclays restated an “overweight” rating and issued a GBX 429 price target on shares of Beazley in a research note on Friday, November 5th. Berenberg Bank restated a “buy” rating and issued a GBX 490 price target on shares of Beazley in a research note on Tuesday, January 4th. Shore Capital...
    Read more ...

     

  • Wise Sets New 1-Year Low at $588.60

    Wise Sets New 1-Year Low at $588.60

    10 days ago - By ETF Daily News

    Wise plc hit a new 52-week low during trading on Wednesday. The company traded as low as GBX 588.60 and last traded at GBX 628.60 , with a volume of 1931006 shares changing hands. The stock had previously closed at GBX 606.40 .
    Separately, Barclays reissued an “equal weight” rating and set a GBX 895 price objective on shares of Wise in a report on Tuesday, November 30th.
    The company has a market capitalization of £6.48 billion and a price-to-earnings ratio of 5.35. The company's fifty day moving average price is GBX 756.55. The company has a current ratio of 1.06, a quick ratio of 1.06 and...
    Read more ...

     

  • Pinnacle Financial Partners Hits New 52-Week High at $108.59

    Pinnacle Financial Partners Hits New 52-Week High at $108.59

    10 days ago - By ETF Daily News

    Pinnacle Financial Partners, Inc. shares reached a new 52-week high on Wednesday. The stock traded as high as $108.59 and last traded at $108.42, with a volume of 641303 shares trading hands. The stock had previously closed at $106.13.
    A number of equities analysts have commented on PNFP shares. Truist lifted their price objective on shares of Pinnacle Financial Partners from $105.00 to $120.00 and gave the stock a “buy” rating in a research note on Thursday, October 14th. They noted that the move was a valuation call. JPMorgan Chase & Co. lifted their price objective on shares of Pinnacle...
    Read more ...